시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 만성 폐고혈압 치료 시장 보고서(2025년)
Chronic Pulmonary Hypertension Treatment Global Market Report 2025
상품코드 : 1720758
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,324,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,141,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,958,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

만성 폐고혈압 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 5.6%로 성장할 전망이며, 89억 5,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 효과적인 치료법에 대한 수요 증가, 투자 증가, 의약품 개발에 대한 정부 지원 확대, 첨단 치료제에 대한 수요 증가, 의식 증가, 만성 뇌손상 발생률 상승 등에 기인하고 있습니다. 주요 동향으로는 신약 및 치료법 개발, 기술 발전, 제약회사, 연구기관, 헬스케어 기관과의 제휴, 새로운 분자 경로의 특정, 정부 및 헬스케어 기관으로부터의 투자 증가, 새로운 치료법 혁신 등을 들 수 있습니다.

심혈관 질환의 높은 부담은 향후 수년간 만성 폐고혈압 치료 시장의 성장을 가속할 것으로 예측됩니다. 심혈관 질환에는 관상동맥 질환, 심부전, 뇌졸중 등 심장과 혈관에 영향을 미치는 다양한 질환이 포함됩니다. 이러한 질환의 유병률 증가는 건강하지 못한 식생활, 운동 부족, 담배 사용, 과도한 알코올 섭취, 비만, 고혈압, 당뇨병, 고령화 등의 위험 인자와 관련되어 있습니다. 만성 폐고혈압 치료는 폐동맥압을 낮추고 심기능을 개선하며 심부전이나 관련 합병증의 위험을 줄여줌으로써 심장혈관 건강에 중요한 역할을 하고 있습니다. 예를 들어 2023년 12월 호주 정부기관인 호주보건복지연구소는 관상동맥성 심장질환(CHD)으로 인한 의사 인정 사망자 수가 2021년 1만 4,100명에서 2022년 1만 4,900명으로 증가했다고 보고했습니다. 이러한 심혈관 질환의 부담 증가가 만성 폐고혈압 치료 시장 확대에 기여하고 있습니다.

만성 폐고혈압 치료 시장의 주요 기업은 피하 주사와 같은 혁신적인 솔루션을 선호하여 환자의 컴플라이언스를 높이고, 편의성을 향상시키며,보다 초점을 맞춘 치료 옵션을 제공하기 위해 피하주사 등 혁신적인 솔루션을 우선시하고 있습니다. 피하주사는 피하에 지속적으로 약제를 투여함으로써 폐동맥압을 효과적으로 저하시키고 폐고혈압 환자의 혈류를 개선합니다. 예를 들어 2024년 3월 미국 제약회사인 Merck & Co Inc.는 미국 식품의약국(FDA)이 Winrevair(sotatercept-csrk)를 승인했다고 발표해 폐동맥성 폐고혈압(PAH) 치료에 큰 진보를 가져왔습니다. 이 혁신적인 치료법은 PAH에 대한 획기적인 선택지로서 두드러진 효과를 가져옵니다. 임상시험에서는 WHO 기능 분류에서 위약군에서는 14%였던 반면, Winrevair에서는 29%의 환자에서 개선이 인정되어 환자의 QOL의 전체적인 향상으로 이어졌습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Chronic pulmonary hypertension (PH) treatment involves managing elevated blood pressure in the lungs to enhance heart function and overall quality of life. This includes medications to lower pressure, oxygen therapy, and diuretics to alleviate symptoms. Advanced treatments may involve pulmonary rehabilitation, lifestyle modifications, and, if necessary, medical procedures. In severe cases, surgical interventions might be considered.

The primary drug categories for chronic pulmonary hypertension include endothelin receptor antagonists (ERAs), phosphodiesterase (PDE-5) inhibitors, prostacyclin analogs, and soluble guanylate cyclase (SGC) stimulators. ERAs work by blocking endothelin to manage pulmonary hypertension and enhance quality of life. These medications are available in different forms, including oral, intravenous, subcutaneous, and inhalational routes, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic pulmonary hypertension treatment market research report is one of a series of new reports from The Business Research Company that provides chronic pulmonary hypertension treatment market statistics, including the chronic pulmonary hypertension treatment industry global market size, regional shares, competitors with the chronic pulmonary hypertension treatment market share, detailed chronic pulmonary hypertension treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic pulmonary hypertension treatment industry. This chronic pulmonary hypertension treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic pulmonary hypertension treatment market size has grown strongly in recent years. It will grow from $6.82 billion in 2024 to $7.21 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be credited to the rising prevalence of chronic pulmonary hypertension, an increase in drug approvals, favorable reimbursement policies, growing healthcare expenditure, and an aging population.

The chronic pulmonary hypertension treatment market size is expected to see strong growth in the next few years. It will grow to $8.95 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be credited to the rising demand for effective treatments, increasing investments, greater government support for drug development, growing demand for advanced therapeutics, heightened awareness, and the rising incidence of chronic brain injuries. Key trends include the development of new drugs and therapies, technological advancements, collaborations with pharmaceutical companies, research institutions, and healthcare organizations, identification of new molecular pathways, increased investments from governments and healthcare organizations, and the innovation of new therapies.

The high burden of cardiovascular diseases is expected to drive the growth of the chronic pulmonary hypertension treatment market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The increasing prevalence of these diseases is linked to risk factors such as unhealthy diets, physical inactivity, tobacco use, excessive alcohol consumption, obesity, hypertension, diabetes, and aging populations. Chronic pulmonary hypertension treatment plays a crucial role in cardiovascular health by lowering pulmonary artery pressure, improving heart function, and reducing the risk of heart failure and related complications. For example, in December 2023, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that doctor-certified deaths due to coronary heart disease (CHD) increased from 14,100 in 2021 to 14,900 in 2022. This rising burden of cardiovascular diseases is contributing to the expansion of the chronic pulmonary hypertension treatment market.

Leading companies in the chronic pulmonary hypertension treatment market are prioritizing innovative solutions, such as subcutaneous injections, to enhance patient compliance, improve convenience, and offer more targeted treatment options. Subcutaneous injection delivers continuous medication under the skin, effectively lowering pulmonary artery pressure and improving blood flow in patients with pulmonary hypertension. For instance, in March 2024, Merck & Co Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Winrevair (sotatercept-csrk), marking a major advancement in pulmonary arterial hypertension (PAH) treatment. This innovative therapy provides significant benefits, setting it apart as a groundbreaking option for PAH. Clinical trials showed that Winrevair improved WHO functional class in 29% of patients, compared to 14% in the placebo group, leading to overall enhancements in patients' quality of life.

In October 2024, Liquidia Corporation, a US-based biopharmaceutical company, partnered with Pharmosa Biopharm to accelerate the development and commercialization of L606. This collaboration aims to advance L606, an inhaled treprostinil therapy, to enhance treatment options for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Pharmosa Biopharm, a Taiwan-based biotechnology company, specializes in the research, development, and commercialization of pharmaceuticals and medical devices.

Major players in the chronic pulmonary hypertension treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, GSK (GlaxoSmithKline), Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Insmed, Cereno Scientific, Roivant Sciences, LGM Pharma, and Liquidia Technologies.

North America was the largest region in the chronic pulmonary hypertension treatment market in 2024. The regions covered in chronic pulmonary hypertension treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic pulmonary hypertension treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic pulmonary hypertension treatment market consists of revenues earned by entities by providing services such as pharmacological treatment services, cardiopulmonary rehabilitation, telemedicine and remote patient monitoring, oxygen therapy, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pulmonary hypertension treatment market also includes sales of calcium channel blockers, pulmonary artery pressure monitoring systems, inhalation devices, and oxygen therapy equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Pulmonary Hypertension Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic pulmonary hypertension treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for chronic pulmonary hypertension treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic pulmonary hypertension treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Chronic Pulmonary Hypertension Treatment Market Characteristics

3. Chronic Pulmonary Hypertension Treatment Market Trends And Strategies

4. Chronic Pulmonary Hypertension Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chronic Pulmonary Hypertension Treatment Growth Analysis And Strategic Analysis Framework

6. Chronic Pulmonary Hypertension Treatment Market Segmentation

7. Chronic Pulmonary Hypertension Treatment Market Regional And Country Analysis

8. Asia-Pacific Chronic Pulmonary Hypertension Treatment Market

9. China Chronic Pulmonary Hypertension Treatment Market

10. India Chronic Pulmonary Hypertension Treatment Market

11. Japan Chronic Pulmonary Hypertension Treatment Market

12. Australia Chronic Pulmonary Hypertension Treatment Market

13. Indonesia Chronic Pulmonary Hypertension Treatment Market

14. South Korea Chronic Pulmonary Hypertension Treatment Market

15. Western Europe Chronic Pulmonary Hypertension Treatment Market

16. UK Chronic Pulmonary Hypertension Treatment Market

17. Germany Chronic Pulmonary Hypertension Treatment Market

18. France Chronic Pulmonary Hypertension Treatment Market

19. Italy Chronic Pulmonary Hypertension Treatment Market

20. Spain Chronic Pulmonary Hypertension Treatment Market

21. Eastern Europe Chronic Pulmonary Hypertension Treatment Market

22. Russia Chronic Pulmonary Hypertension Treatment Market

23. North America Chronic Pulmonary Hypertension Treatment Market

24. USA Chronic Pulmonary Hypertension Treatment Market

25. Canada Chronic Pulmonary Hypertension Treatment Market

26. South America Chronic Pulmonary Hypertension Treatment Market

27. Brazil Chronic Pulmonary Hypertension Treatment Market

28. Middle East Chronic Pulmonary Hypertension Treatment Market

29. Africa Chronic Pulmonary Hypertension Treatment Market

30. Chronic Pulmonary Hypertension Treatment Market Competitive Landscape And Company Profiles

31. Chronic Pulmonary Hypertension Treatment Market Other Major And Innovative Companies

32. Global Chronic Pulmonary Hypertension Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Pulmonary Hypertension Treatment Market

34. Recent Developments In The Chronic Pulmonary Hypertension Treatment Market

35. Chronic Pulmonary Hypertension Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기